# A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)

> **NCT02483312** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 9 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** IL-12

## Key facts

- **NCT ID:** NCT02483312
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-09
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2025-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02483312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02483312, "A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT02483312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*